MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Depression"

  • 2019 International Congress

    The effect of istradefylline on mood disorders in Parkinson’s disease

    H. Nagayama, O. Kano, H. Murakami, M. Hamada, R. Sengoku, Y. Shim, T. Toda (Tokyo, Japan)

    Objective: The effectiveness of istradefylline for treatment of mood disorders in patients with Parkinson's disease (PD) was examined in an open-label trial. Background: Depression is…
  • 2019 International Congress

    Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

    J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

    Objective: We are assessing use of pimavanserin (PIM) for treatment of depression in adults with PD. Background: Depression occurs in ~50% of Parkinson’s disease (PD)…
  • 2019 International Congress

    The effects of zonisamide on motor and non-motor symptoms in patients with Parkinson’s disease: a 3-month open-label study

    K. Suzuki, H. Fujita, T. Matsubara, T. Kadowaki, K. Funakoshi, Y. Watanabe, T. Shiina, H. Sakuramoto, M. Hamaguchi, K. Hirata (Tochigi, Japan)

    Objective: To investigate the effect of zonisamide (ZNS) on motor and non-motor symptoms, such as depressive symptoms and sleep problems, in patients with Parkinson’s disease…
  • 2019 International Congress

    Higher levels of physical activity is associated with fewer non-motor symptoms in early Parkinson’s disease: a 1-year follow-up study

    S. Ng, N. Chia, M. Abbas, KY. Tay, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To examine the physical activity (PA) level in early Parkinson’s disease (PD) patients and its association with non-motor symptoms (NMS). Background: Lower PA is…
  • 2019 International Congress

    Vortioxetine treatment of depression in Parkinson’s disease

    M. Russo, C. Carrarini, F. Dono, L. Ferri, M. Di Pietro, M. Onofrj (Chieti, Italy)

    Objective: To assess efficacy and safety of Vortioxetine in Parkinson’s Disease (PD) patients affected by depression and its effects on motor performance. Background: Depression is…
  • 2019 International Congress

    Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

    M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

    Objective: The aim of this project was to evaluate high-fat diet (HFD) induced behavioral alterations in the A53T alpha-Synuclein Parkinsons’s disease mouse model. Background: Besides…
  • 2019 International Congress

    Influence of Cognitive Deficits and Tremor Severity of the Development of Depression in Nondemented Patients with Essential Tremor

    M. Petrova, O. Grigorova, M. Raycheva, L. Traykov (Sofia, Bulgaria)

    Objective: The aim of this study was to investigate the relationship between cognitive deficits and tremor severity with the development of depression in nondemented ET…
  • 2019 International Congress

    Neuropsychiatric manifestations in Parkinson’s disease

    O. Cherkaoui Rhazouani, N. Jalami, M. Chraa, N. Kissani (Marrakech, Morocco)

    Objective: Evaluate the different neuropsychiatric manifestations in Parkinson's disease. Background: Parkinson's disease (PD) is the second most common neurodegenerative pathology after Alzheimer's disease, although PD…
  • 2019 International Congress

    Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease

    SZ. Wei, F. Wang, CF. Liu (Suzhou, China)

    Objective: The aim of this study is to understand if the antidepressant effect of pramipexole is mediated by D2R or D3R in a mouse model…
  • 2019 International Congress

    Pursuit of Psychosocial Intervention for Depression and Anxiety in Japanese Parkinson’s Disease patients: Two Studies of Cognitive Behavioral Therapy

    I. Shinmei, N. Nishikawa (Tokyo, Japan)

    Objective: From 2013 to the present, we have explored the feasibility of cognitive behavioral therapy (CBT) for Japanese Parkinson’s disease (PD) patients with depression and…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley